An analysis of FDA complete response letters does not reveal a big uptick – but the year is not over yet.
A decision is due on Bristol’s new leukaemia project, while Mallinckrodt and Mesoblast await their fates after mixed panel meetings.
A Vantage analysis suggests which small biotechs might seriously have to rethink R&D spending plans in the wake of Covid-19.
Hints of activity, generated by academic centres, suggest that antivirals and an antimalarial might play some role against Covid-19.
Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.